Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.

Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies. - Efficacy of aprepitant in the chemotherapies for hematologic malignancies.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006690

Enrollment

Registered

2011-11-09

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancies

Interventions

course 1 aprepitant (-) course 2- aprepitant (+) course 1 aprepitant (+) course 2- aprepitant (+)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients (>=20 years-old) with hematologic malignancies treated with cancer chemotherapies including moderately emetogenic agents or highly emetogenic agents

Exclusion criteria

Exclusion criteria: patients unable to answer the questions about efficacy of aprepitant

Design outcomes

Primary

Measure	Time frame
conplete response (no vomiting, no salvage treatment) in day1 through 7.	—

Secondary

Measure	Time frame
complete response, frequency of nausea and vomiting, meal status, weight change	—

Countries

Japan

Contacts

Public ContactKimiharu Uozumi

Kagoshima University Hospital Hematoilogy and Immunology

uosakana@m.kufm.kagoshima-u.ac.jp099-275-5934

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026